_256_384.jpg)
Medical Device | November 01, 2021
Holborn Wells and SpeedBio India forms JV to manufacture in vitro diagnostics
Both parties are expected to invest a total of US $ 1 million to establish the brand
Both parties are expected to invest a total of US $ 1 million to establish the brand
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
Cipla has reported consolidated financial results for the period ended September 30, 2021
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
Subscribe To Our Newsletter & Stay Updated
